删除第一项中无关的 "制造商 "一词
2月19日 - ** 摩根大通将制药商Pacira Biosciences PCRX.O的PT值从11美元上调至21美元
** 新的目标价较该股上次收盘价下跌了 20.6
** 表示维持其 "减持 "评级，上调PT "主要反映了仿制药进入市场的时间较晚"。
** 券商称，公司当前约 26 美元的股价意味着市场假设公司的疼痛治疗药物 Exparel 将于 2035 年以上进入仿制药市场，券商认为这对 PCRX 来说是 "非常乐观的情景"，低估了 "竞争风险"。
** 称 "假定本十年末进入市场的结果更为平衡"。
** 该公司的主导药物 Exparel 是一种手术后疼痛控制药物
** 股价在过去 12 个月下跌了 11.4
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.